Literature DB >> 12200773

Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations.

Louis Libbrecht1, Didier Bielen, Chris Verslype, Dirk Vanbeckevoort, Jacques Pirenne, Frederik Nevens, Valeer Desmet, Tania Roskams.   

Abstract

Imaging detection and diagnosis of hepatocellular carcinomas (HCCs) and dysplastic nodules (DNs) in cirrhotic patients is important because the number, size, and type of focal lesions strongly influence patient management. Focal lesions detected by imaging examinations during pretransplantation evaluation were correlated with focal lesions detected during detailed pathological examination of 49 cirrhotic explant livers. Within 6 months before transplantation, color Doppler ultrasonography (US), contrast-enhanced computed tomography (CT), and magnetic resonance (MR) imaging were performed in 94%, 33%, and 55% of patients, respectively. In 2% to 8% of patients, different types of benign focal lesions were present, and a considerable proportion was interpreted as (pre)malignant on imaging examination. US detected only the largest HCCs (patient sensitivity, 40%; specificity, 100%) and no DNs. On a per-patient basis, contrast-enhanced CT and MR imaging had poor sensitivity (20% and 27%, respectively) and good specificity (100% and 94%, respectively) for DNs. Patient sensitivity and specificity of both techniques for HCC were reasonable (50% for CT, 70% for MR imaging) and good (79% for CT, 82% for MR imaging), respectively. Neither technique was able to detect smaller (pre)malignant lesions. As a consequence, 10% of patients underwent transplantation, although they exceeded the tumor number limit. Currently used imaging techniques cannot correctly determine the exact tumor burden in some cirrhotic patients. Regular contrast-enhanced MR examination of cirrhotic patients waiting for liver transplantation is the best tool for the early detection of (pre)malignant lesions.

Entities:  

Mesh:

Year:  2002        PMID: 12200773     DOI: 10.1053/jlts.2002.34922

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  34 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation.

Authors:  Carlos Nicolau; Violeta Catalá; Ramón Vilana; Rosa Gilabert; Luis Bianchi; Manel Solé; Mario Pagés; Concepció Brú
Journal:  Eur Radiol       Date:  2004-03-09       Impact factor: 5.315

3.  Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population.

Authors:  Min Jung Park; Young-Sun Kim; Won Jae Lee; Hyo K Lim; Hyunchul Rhim; Jongmee Lee
Journal:  Eur Radiol       Date:  2010-06-19       Impact factor: 5.315

4.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

5.  Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound.

Authors:  Grace Lai-Hung Wong; Hui-Xiong Xu; Xiao-Yan Xie
Journal:  World J Radiol       Date:  2009-12-31

6.  Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.

Authors:  Sonja K Olsen; Robert S Brown; Abby B Siegel
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

7.  Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma.

Authors:  Vincent Vandecaveye; Frederik De Keyzer; Chris Verslype; Katya Op de Beeck; Mina Komuta; Baki Topal; Ilse Roebben; Didier Bielen; Tania Roskams; Frederik Nevens; Steven Dymarkowski
Journal:  Eur Radiol       Date:  2009-05-14       Impact factor: 5.315

8.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

9.  Progenitor-derived hepatocellular carcinoma model in the rat.

Authors:  Jesper B Andersen; Roberto Loi; Andrea Perra; Valentina M Factor; Giovanna M Ledda-Columbano; Amedeo Columbano; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

10.  Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan.

Authors:  Satoru Todo; Hiroyuki Furukawa
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.